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mice and these differences conﬁrmed by RT-qPCR for Myf6 and Myh1.
Comparison of Str/ort mice at these same ages, during which OA develops,
showed 279 differentially regulated genes (47 up, 232 down) and these
were mainly centred on the signalling via the NFkB complex.
To determine the gene expression patterns related to OA susceptibility,
8wk-old CBA and Str/ort mice AC were compared. This showed up-regula-
tionof 139genes (nonedown-regulated), includingHtra1 andTIMP1,which
was again centred primarily on NFkB pathway signalling. Immunolabelling
ofAC sections showed that theNfkB-p65proteinwasmorehighlyexpressed
in chondrocytes of 8wk-old Str/ort than in aged-matched CBA mice.
To deﬁne gene proﬁles speciﬁc to early OA, AC from 8 and 18wks old Str/ort
mice was compared. This showed 113 down-regulated and only 2 up-
regulated genes and pathway analysis showed that these were again
centred on the NFkB pathway. Interestingly, no genes were differentially
regulated between 18 and 40wks in Str/ort mice, suggesting that similar
processes are taking place in both early and late-stage OA.
Conclusions: We ﬁnd that AC chondrocytes express skeletal muscle-
related genes in young mice that are lost during normal healthy ageing but
retained during OA. In addition, our data support the involvement of NFkB
pathway signalling in susceptibility of AC to spontaneous OA and to OA
progression. This study highlights these molecular processes as possible
markers of OA and targets for slowing OA development.
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GENERATION OF AN INDUCIBLE CARTILAGE SPECIFIC DELETER USING
HUMAN AGGRECAN ENHANCER/PROMOTER THAT IS TRACKABLE IN
VIVO USING LUCIFERASE
G. Bou-Gharios, A. Layyous, K. Liu, H. Nakamura, L. Lo Cascio,
J. Saklatvala. Kennedy Inst. of Rheumatology, London, United Kingdom
Purpose: To generate a chondrocyte-speciﬁc deleter which can be
visualised in vivo. We needed an improvement on the collagen type II
which is signiﬁcantly reduced in adult articular cartilage and expresses in
kidney during development
Methods:We have utilized a transgenic approach where we have used the
human aggrecan enhancer/promoter to drive inducible Cre recombinase
(Cre-ERT2) followed by an IRES luciferase forming a bicistronic mRNA in
transgenic mice.
Results:The expression and efﬁciencyof the inducible cre recombinasewas
tested by examining X-gal staining of tissues from embryos as well as adult
in double transgenic with Rosa 26R mice. Cre recombinase was induced by
tamoxifen, at different time points during development and postnatally. X-
gal staining was observed in growth plate and articular cartilage as well as
theﬁbrocartilage ofmeniscus, trachea, and intervertebral discs reproducing
the pattern of endogenous aggrecan gene expression.
In addition to this mouse being an efﬁcient deleter, the presence of lucif-
erase allows the visualization of aggrecan expression in vivo. This has been
tested before or after the induction of osteoarthritis through destabilisa-
tion of the medial meniscus ligament up to eight weeks post surgery.
Conclusions: The aggrecan-CreERT2 will help us determine genes
involvement in the integrity of the cartilage and visualize this complex in
osteoarthritis
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DEFICIENCY OF NFAT1 TRANSCRIPTION FACTOR CAUSES
OSTEOARTHRITIS WITH ALTERATIONS IN ARTICULAR CARTILAGE AND
SUBCHONDRAL BONE IN ADULT MICE
J. Wang, B. Gardner, Q. Lu, M. Shaath, K. Brandt, H. Anderson. Univ. of
Kansas Med. Ctr., Kansas City, KS, USA
Purpose: One of the barriers to progress in OA research is the difﬁculty in
obtaining human joint tissue samples at an early stage of OA that permits
studies of the mechanisms for initiation of OA. Many animal models have
been developed to explore the mechanisms of human OA. However,
surgically- or chemically-induced OA models often display rapidly
progressive joint lesions and may not be suitable for studying the etio-
pathogenesis of more slowly progressive non-traumatic OA in humans.
Murine models of OA developed by spontaneous or genetically-inducedmutations of genes for cartilage matrix proteins or growth factors are often
accompanied by developmental defects in the skeletal system (e.g., mice
harboringmutations in aggrecan or type-II collagen). Notably, these mouse
models usually do not show subchondral bone changes, an important
pathogenetic feature of human OA. Therefore, there is a crucial need for
animal models that mimic the pathologic characteristics of idiopathic
human OA to study the mechanisms for initiation and progression of OA.
Methods: We examined whether deletion of Nfat1, a transcription factor
previously reported as a regulator of the expression of cytokine genes
during the immune response, would alter the expression of speciﬁc
proinﬂammatory cytokines and display osteoarthritic changes in articular
tissues of mice.
Results: The results revealed that deletion of Nfat1 transcription factor in
mice caused classic OA changes, including alterations in articular cartilage
and subchondral bone that mimic those in human OA. Nfat1-deﬁcient mice
exhibited normal skeletal development but displayed loss of type-II collagen
and aggrecan in young adult articular cartilage of load-bearing joints. These
early changes were followed by articular chondrocyte proliferation/clus-
tering, thickening of subchondral bone, slow progression of articular surface
destruction, and formation of chondro-osteophytes. Overexpression of
speciﬁc matrix-degrading proteinases and proinﬂammatory cytokines was
observed in Nfat1-deﬁcient articular cartilage and synovium. We identiﬁed
Nfat1 binding sites in the promoters of the genes for mouse and human
interleukin-1b, tumor necrosis factor-a, matrix metalloproteinase-13
(MMP13), and a disintegrin and metalloproteinase with thrombospondin
motifs-4,5 (ADAMTS-4,5), suggesting that Nfat1 may be an upstream regu-
lator of these catabolic molecules that degrade articular cartilage.
Conclusions: These novel ﬁndings suggest that Nfat1-deﬁcient mouse
may serve as a more suitable surrogate of human OA than murine OA
models that do not exhibit subchondral bone changes. Because Nfat1
regulates multiple matrix-degrading proteinases and proinﬂammatory
cytokines in articular tissues, anti-OA agents that target Nfat1 could be
more effective than drug candidates that target a single catabolic molecule.
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EARLY INTERVENTION TO PREVENT CARTILAGE DEGENERATION BY
ADMINISTRATION OF ANTI-VEGF ANTIBODY IN RABBIT MODEL
T. Nagai, M. Sato, T. Kutsuna, T. Ukai, M. Kobayashi, J. Mochida. Tokai Univ.,
Kanagawa Isehara, Japan
Purpose: We have previously constructed and transplanted scaffold-free
tissue-engineered cartilage into an osteochondral defect (Tissue Eng Part A
2008;14:1183-1193), and conﬁrmed that reparative cells derived from
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restorative effects of articular cartilage (Tissue Eng Part A 2008;14:1225-
1235.). Then we reported that intravenous administration of bevacizumab,
a humanized monoclonal anti-VEGF antibody contributes to the repair of
articular cartilage in an osteochondral defect model (Arthritis research and
therapy 2010,12:R178.). The object of this study was to investigatewhether
cartilage degeneration is prevented following intravenous administration
of bevacizumab in the rabbit model of anterior cruciate ligament tran-
section (ACLT).
Methods: ACLT rabbits were classiﬁed into two groups: Group B, admin-
istration of bevacizumab (n¼15; 100 mg intravenous injection on the day
of 1 and 3 weeks after surgery); and the Control (n¼16).
Osteophyte formation was evaluated macroscopically and OA repair sites
were also evaluated using OARSI modiﬁed Mankin score.
Results: One month after ACLT, macroscopic evaluation of both groups
showed some parts of joints included osteophyte formation and almost
smooth joints surface of the articular cartilage (Figure.1). However histo-
logic assessment demonstrated that articular cartilage was recognized loss
of staining in Control. Group B was tended to retain staining (Figure.2).
3 months after ACLT, macroscopic evaluation of the Control showed
marked progression of arthritis and osteophyte formation. Group B still
showed smooth joint surfaces in the most regions of the articular cartilage
and osteophyte formation was restrained (Figure.3, 4).Ă
ĂOARSI histological score was used to evaluate the quality of the repair
tissue (Figure.5). Osteophyte formation score 3 month after ACLT in B
group was signiﬁcantly lower than control (Figure.6).
Conclusions: The early intervention of intravenous administration of
bevacizumabwould be useful to prevent the post-traumatic osteoarthritis.
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DIFFERENCES IN STRUCTURAL AND PAIN PHENOTYPES BETWEEN
MONOIODOACETAE AND MENISCAL TRANSECTION MODELS OF
OSTEOARTHRITIS
P.I. Mapp 1, D.R. Sagar 1,2, S. Ashraf 1, S. Suri 1, V. Chapman 1,2,
D.A. Walsh 1. Arthritis Research UK Pain Centre, University of Nottingham,
UK. 1Univ. of Nottingham, Nottingham, UNITED KINGDOM; 2 Sch. of BioMed.
Sci., University of Nottingham, United Kingdom
Purpose: To compare pathology in two animal models of osteoarthritis at
several time points after the induction of arthritis and to investigate pain
behaviour over the course of the experiment.
Methods:Meniscal transection (MNX) arthritis was induced by transection
of the meniscus in 180g male Sprague Dawley rats. Controls were animals
subjected to sham surgery in which the collateral ligament was removed
but the meniscus was left intact. Monosodium iodoacetate(MIA) arthritis
was induced by the intra-articular injection of 1mg of sodium mono-
iodacetate dissolved in 50ml sterile saline. Separate groups of animals
injected with saline were controls. Groups of animals (n¼8) were sacri-
ﬁced at 14, 35 and 45 days. Pain behaviour was monitored by differential
weight bearing (g) and paw withdrawal thresholds (g). Pathology was
scored for synovial inﬂammation (0-3), chondropathy (0-15), osteophytes
(0-3) and the number of osteochondral channels /mm length of cartilage
were counted. Data are means (95% CI).
Results: Inﬂammation in the synovium remained constant over time. At
day 49, MNX- treated knees had greater inﬂammation 1.7 (1.2-2.1) than
Sham controls 0.2 (0.02-0.4) p<0.01, and MIA- treated knees were more
inﬂamed 0.6 (0.2-0.8) than saline-injected controls 0.0 (0-0). MNX- treated
knees were more inﬂamed than MIA -treated knees, p> 0.01. Osteophyte
scores were greater at all time points in MNX- treated knees when
compared to MIA -treated knees. At day 49 osteophytes scores were
greater in MNX- treated knees 2.8 (2.6-3.0) than sham 0.23 (0.02-0.4),
p<0.01, and greater in MIA-treated knees 1.0 (0.5-1.4) than in saline-
injected controls 0 (0-0), p<0.01. Osteophyte scores were greater in MNX-
treated knees than in MIA-treated knees (p<0.01). Chondropathy scores
increased in both treatment groups with time and did not differ between
MNX-treated knees and MIA-treated knees. At day 49 MNX-treated knees
had higher osteophyte scores 12.7 (11.1-14.3) than sham controls 2.8 (0.8-
4.8), p<0.01. Osteophyte scores in MIA-treated knees 9.7 (7.5-11.8) were
higher than in saline controls 0 (0-0), p<0.01. At day 49 MNX-treated
animals displayed greater numbers of channels crossing the osteochondral
junction 0.25 (0.1-0.4) channels/mm compared to sham controls 0.01
(0.03-0.1), MIA-treated knees 0.1 (0.09-0.1) and saline controls 0.04 (0.01-
0.2). MNX- treated animals displayed greater weight bearing asymmetry
